Patents by Inventor Edward Andrew Boyd
Edward Andrew Boyd has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8852937Abstract: The present invention makes available methods and reagents for modulating proliferation or differentiation in a cell or tissue comprising contacting the cell with a hedgehog agonist, such as the compounds depicted in FIGS. 32 and 33. In certain embodiments, the methods and reagents may be employed to correct or inhibit an aberrant or unwanted growth state, e.g., by antagonizing a normal ptc pathway or agonizing smoothened or hedgehog activity.Type: GrantFiled: August 20, 2007Date of Patent: October 7, 2014Assignee: Curis, Inc.Inventors: Anthony David Baxter, Edward Andrew Boyd, Maria Frank-Kamenetsky, Oivin Guicherit, Jeffery Porter, Stephen Price, Lee Rubin, John Harry Alexander Stibbard
-
Patent number: 8815895Abstract: The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function comprising contacting the cell with a hedgehog antagonist of formula (I) in a sufficient amount to aberrant growth state, e.g., to agonize a normal ptc pathway or antagonize smoothened or hedgehog activity.Type: GrantFiled: March 16, 2012Date of Patent: August 26, 2014Assignees: Curis, Inc., Genentech, Inc.Inventors: Oivin M. Guicherit, Edward Andrew Boyd, Shirley Ann Brunton, Stephen Price, John Harry Alexander Stibbard, Colin H. Mackinnon
-
Patent number: 8772275Abstract: The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function comprising contacting the cell with a hedgehog antagonist, such as a small molecule, in a sufficient amount to aberrant growth state, e.g., to agonize a normal ptc pathway or antagonize smoothened or hedgehog activity.Type: GrantFiled: December 12, 2012Date of Patent: July 8, 2014Assignee: Curis, Inc.Inventors: Lee L. Rubin, Oivin Guicherit, Stephen Price, Edward Andrew Boyd
-
Patent number: 8354397Abstract: The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function comprising contacting the cell with a hedgehog antagonist, such as a small molecule, in a sufficient amount to aberrant growth, e.g., to agonize a normal ptc pathway or antagonize smoothened or hedgehog activity.Type: GrantFiled: July 29, 2002Date of Patent: January 15, 2013Assignee: Curis, Inc.Inventors: Lee L. Rubin, Oivin Guicherit, Stephen Price, Edward Andrew Boyd
-
Patent number: 8314257Abstract: The present invention provides indole derivatives that antagonize prostaglandin D2, and that can be used to treat inflammatory diseases mediated by prostaglandin D2.Type: GrantFiled: September 17, 2008Date of Patent: November 20, 2012Assignee: Oxagen LimitedInventors: David Middlemiss, Mark Richard Ashton, Edward Andrew Boyd, Frederick Arthur Brookfield, Michael George Hunter, Mark Whittaker, Chris Palmer, Eric R. Pettipher
-
Publication number: 20120283258Abstract: The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function comprising contacting the cell with a hedgehog antagonist of formula (I) in a sufficient amount to aberrant growth state, e.g., to agonize a normal ptc pathway or antagonize smoothened or hedgehog activity.Type: ApplicationFiled: March 16, 2012Publication date: November 8, 2012Applicants: CURIS, INC., GENENTECH, INC.Inventors: Oivin M. GUICHERIT, Edward Andrew BOYD, Judith Boyd, Shirley Ann BRUNTON, Stephen PRICE, John Harry Alexander STIBBARD, Colin H. MACKINNON
-
Patent number: 8198298Abstract: Compounds which are pyrrolo[2,3-b]pyridine derivatives or pharmaceutically acceptable salts thereof, their preparation process and pharmaceutical compositions comprising them are disclosed; these compounds are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders; also disclosed is a process under SPS conditions for preparing the compounds of the invention and chemical libraries comprising a plurality of them.Type: GrantFiled: February 14, 2011Date of Patent: June 12, 2012Assignee: Pfizer Italia S.r.l.Inventors: Barbara Salom, Matteo D'Anello, Maria Gabriella Brasca, Patrizia Giordano, Katia Martina, Dania Tesei, Frederick Arthur Brookfield, William John Trigg, Edward Andrew Boyd, Jonathan Anthony Larard
-
Patent number: 8198314Abstract: The present invention provides indole derivatives that antagonize prostaglandin D2, and that can be used to treat inflammatory diseases mediated by prostaglandin D2.Type: GrantFiled: September 17, 2008Date of Patent: June 12, 2012Assignee: Oxagen LimitedInventors: David Middlemiss, Mark Richard Ashton, Edward Andrew Boyd, Frederick Arthur Brookfield, Michael George Hunter, Mark Whittaker, Chris Palmer, Eric R. Pettipher
-
Patent number: 8168653Abstract: The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function comprising contacting the cell with a hedgehog antagonist of formula (I) in a sufficient amount to aberrant growth state, e.g., to agonize a normal ptc pathway or antagonize smoothened or hedgehog activity.Type: GrantFiled: August 2, 2010Date of Patent: May 1, 2012Assignees: Curis, Inc., Genentech, Inc.Inventors: Oivin M. Guicherit, Edward Andrew Boyd, Shirley Ann Brunton, Stephen Price, John Harry Alexander Stibbard, Colin H. Mackinnon
-
Patent number: 8163936Abstract: The present invention provides indole derivatives that antagonize prostaglandin D2, and that can be used to treat inflammatory diseases mediated by prostaglandin D2.Type: GrantFiled: September 17, 2008Date of Patent: April 24, 2012Assignee: Oxagen LimitedInventors: David Middlemiss, Mark Richard Ashton, Edward Andrew Boyd, Frederick Arthur Brookfield, Michael George Hunter, Mark Whittaker, Chris Palmer, Eric R. Pettipher
-
Patent number: 8163931Abstract: The present invention provides indole derivatives that antagonize prostaglandin D2, and that can be used to treat inflammatory diseases mediated by prostaglandin D2.Type: GrantFiled: September 17, 2008Date of Patent: April 24, 2012Assignee: Oxagen LimitedInventors: David Middlemiss, Mark Richard Ashton, Edward Andrew Boyd, Frederick Arthur Brookfield, Michael George Hunter, Mark Whittaker, Chris Palmer, Eric R. Pettipher
-
Patent number: 8129425Abstract: The present invention makes available methods and reagents for modulating proliferation or differentiation in a cell or tissue comprising contacting the cell with a hedgehog agonist, such as the compounds depicted in FIGS. 32 and 33. In certain embodiments, the methods and reagents may be employed to correct or inhibit an aberrant or unwanted growth state, e.g., by antagonizing a normal ptc pathway or agonizing smoothened or hedgehog activity.Type: GrantFiled: April 27, 2006Date of Patent: March 6, 2012Assignee: Curis, Inc.Inventors: Anthony David Baxter, Edward Andrew Boyd, Maria Frank-Kamenetsky, Oivin Guicherit, Jeffery Porter, Stephen Price, Lee Rubin, John Harry Alexander Stibbard
-
Patent number: 8106069Abstract: Compounds which are pyrrolo[2,3-b]pyridine derivatives or pharmaceutically acceptable salts thereof, their preparation process and pharmaceutical compositions comprising them are disclosed; these compounds are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders; also disclosed is a process under SPS conditions for preparing the compounds of the invention and chemical libraries comprising a plurality of them.Type: GrantFiled: April 23, 2010Date of Patent: January 31, 2012Assignee: Pfizer Italia S.r.l.Inventors: Barbara Salom, Matteo D'Anello, Maria Gabriella Brasca, Patrizia Giordano, Katia Martina, Francesco Angelucci, Frederick Arthur Brookfield, William John Trigg, Edward Andrew Boyd, Jonathan Anthony Larard
-
Patent number: 8080567Abstract: A compound of formula (III): or a salt, solvate and chemically protected form thereof, wherein: R5 is an optionally substituted C5-20 aryl or C4-20alkyl group; L? is a single bond, —O— or —C(?O)—; A is selected from the group consisting of: formula (i) (ii) (iii) wherein X and Y are selected from the group consisting of: O and CR3; S and CR3; NH and CR3; NH and N; O and N; S and N; N and S; and N and O, and where the dotted lines indicate a double bond in the appropriate location, and where Q is either N or CH; D is selected from: formula (i) (ii) (iii) (iv) (v) (vii) (viii) (ix) B is selected from the group consisting of: formula (A) (B) where RP6 is selected from fluoro and chloro; and R2 is either: (i) —CO2H; (ii) —CONH2; (iii) —CH2—OH; or (iv) tetrazol-5-yl.Type: GrantFiled: August 9, 2006Date of Patent: December 20, 2011Assignee: Asterand UK LimitedInventors: Alexander William Oxford, Richard Jon Davis, Robert Alexander Coleman, Kenneth Lyle Clark, David Edward Clark, Shirley Ann Brunton, Neil Victor Harris, Garry Fenton, George Hynd, Keith Alfred James Stuttle, Jonathan Mark Sutton, Mark Richard Ashton, Edward Andrew Boyd
-
Patent number: 8044088Abstract: Compounds of general formula (I) wherein R1 is halo or cyano; R2 is C1-C4 alkyl; and R3 is phenyl substituted with one or more substituents chosen from C1-C6 alkyl, halo or —SO2(C1-C6 alkyl); or a pharmaceutically acceptable salt, hydrate, solvate, complex or prodrug thereof; are useful in the treatment of diseases and conditions mediated by the action of PGD2 at the CRTH2 receptor.Type: GrantFiled: March 10, 2006Date of Patent: October 25, 2011Assignee: Oxagen LimitedInventors: Richard Edward Armer, Edward Andrew Boyd, Judith Helen Boyd, legal representative, Philip Andrew Hay
-
Publication number: 20110136857Abstract: Compounds which are pyrrolo[2,3-b]pyridine derivatives or pharmaceutically acceptable salts thereof, their preparation process and pharmaceutical compositions comprising them are disclosed; these compounds are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders; also disclosed is a process under SPS conditions for preparing the compounds of the invention and chemical libraries comprising a plurality of them.Type: ApplicationFiled: February 14, 2011Publication date: June 9, 2011Applicant: PFIZER ITALIA S.R.L.Inventors: Barbara Salom, Matteo D'Anello, Maria Gabriella Brasca, Patrizia Giordano, Katia Martina, Dania Tesei, Frederick Arthur Brookfield, William John Trigg, Edward Andrew Boyd, Jonathan Anthony Larard
-
Patent number: 7888508Abstract: Compounds which are pyrrolo[2,3-b]pyridine derivatives or pharmaceutically acceptable salts thereof, their preparation process and pharmaceutical compositions comprising them are disclosed; these compounds are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders; also disclosed is a process under SPS conditions for preparing the compounds of the invention and chemical libraries comprising a plurality of them.Type: GrantFiled: December 23, 2004Date of Patent: February 15, 2011Assignee: Pfizer Italia S.r.l.Inventors: Barbara Salom, Matteo D'Anello, Maria Gabriella Brasca, Patrizia Giordano, Katia Martina, Dania Tesei, Frederick Arthur Brookfield, William John Trigg, Edward Andrew Boyd, Jonathan Anthony Larard
-
Publication number: 20100330077Abstract: Compounds of general formula (I) wherein R1 is halo or cyano; R2 is C1-C4 alkyl; and R3 is phenyl substituted with one or more substituents chosen from C1-C6 alkyl, halo or —SO2(C1-C6 alkyl); or a pharmaceutically acceptable salt, hydrate, solvate, complex or prodrug thereof; are useful in the treatment of diseases and conditions mediated by the action of PGD2 at the CRTH2 receptor.Type: ApplicationFiled: March 10, 2006Publication date: December 30, 2010Applicant: OXAGEN LIMITEDInventors: Richard Edward Armer, Edward Andrew Boyd, Philip Andrew Hay
-
Publication number: 20100317660Abstract: The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function comprising contacting the cell with a hedgehog antagonist of formula (I) in a sufficient amount to aberrant growth state, e.g., to agonize a normal ptc pathway or antagonize smoothened or hedgehog activity.Type: ApplicationFiled: August 2, 2010Publication date: December 16, 2010Inventors: Oivin M. Guicherit, Edward Andrew Boyd, Judith Boyd, Shirley Ann Brunton, Stephen Price, John Harry Alexander Stibbard, Colin H. Mackinnon
-
Patent number: 7816369Abstract: The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function comprising contacting the cell with a hedgehog antagonist, such as a small molecule, in a sufficient amount to aberrant growth state, e.g., to agonize a normal ptc pathway or antagonize smoothened or hedgehog activity.Type: GrantFiled: November 3, 2005Date of Patent: October 19, 2010Assignees: Curis, Inc., Genentech, Inc.Inventors: Oivin M. Guicherit, Edward Andrew Boyd, Judith Boyd, legal representative, Shirley Ann Brunton, Stephen Price, John Harry Alexander Stibbard, Colin H. MacKinnon